This mass-spectrometncmethod for assaying tocainide in serum is specific, reproducible, and sensitive, and sample preparation is rapid. The drug is isolated from serum by liquid-solid extraction on a Baker C18 disposable column. Undenvatizeddrug is separated by elutionon a 0.20 mm x 25 m fused-silica capillary column coated with 5% phenylmethylsilicone,then quantified by mass-selectivedetection (selected ion monitoring).Sample size is 1 mL of serum, but smaller volumes may be used. Mean analyticalrecoveryof the drug from the disposable columns is 75%. Commonly used antiarthythmlcs, sedatives, or hypnoticsdo not interfere. The run-to-runCV at 3.7 mg/L is 4.0%, 3.0% at 10.5 mg/L.
to each column; the final concentration of internal standard is 5 mg/L. Wash the columns with two column volumes of distilled water, dry them by aspirating air through them, and elute the drug by adding 600 p.L of an equivolume solution of chloroform/acetone.
Remove the eluent by evaporation under constant air flow in a water bath set at 37#{176}C. Reconstitute the residue with 50 pL of methanol and inject 1 p.1.. of this into the gas chromatograph-mass spectrometer
(G(MS).
GC/MS assay. I used instrumentation from HewlettPackard, Palo Alto, CA, consisting of an HP 7914 computer, which serves as both controller and output device; an HP 9000 keyboard and color-graphics monitor; an HP 7550A X-Y plotter; an HP 5890A gas chromatograph equipped for fused silica capillary gas chromatography;
and an HP 5970 mass selective detector. The detector is equipped with a 70-eV electron impact ionization source, a hyperbolic quadrapole mass analyzer, an electron multiplier detector, and a turbomolecular pump for maintaining low pressure. Pa. Operating parameters for the mass spectrometerwere adjusted with the HP "Autotune" provided with the mass selective detector, with perfluorotributylamine as the calibration compound.
Recovery study. Analytical recovery of tocaithde from serum was determined by comparing peak heights of the extracted drug with peak heights of the corresponding drug obtained by direct injection of samples and quantification by the liquid-chromatographic method I previously reported (4). Drug-interference studies. I tested several drugs for potential interference by injecting extracts of pisoms containing the drugs into the OS/MS. Figures 1 and 2 show total ion chromatograms and tracings of rnlz 192 and m/z 206 for a drug-free serum sample to which internal standard was added, and a serum sample from a patient on tocaunide therapy, to which internal standard also was added. The drug and the internal standard are clearly resolved, and there are no interferences from serum components or trace materials in the internal standard. The extraction procedure and chromatographic conditions resulted in a linear response for peak area ratio (mlz 192/206) as a function of tocainide concentration from 1 to 32 mg/L (y = 0.124x + 0.0486; r = 0.999). The sensitivity of the assay permits use of relatively small volumes of sample. Good standard curves have been obtained with as little as 100 pL of serum, and analytical recovery of tocainide from serum is 75%. Figure 3 shows mass spectra for tocainide and N-(2,6-dimethylphenyl)-2-aminobutanamide.
Results and DiscussIon

IC
As can be seen, the molecular ions are abundant enough to permit specific quantification.
I determined the precision of the method at two drug concentrations.
Drug-free sera were supplemented with Table 1 lists non-interfering drugs; added to serum and taken through the extraction procedure, all the drugs listed were eluted from the capillary column at retention times different from that of tocainide or the internal standard. This, combined with selected ion monitoring of the molecular ions of tocainide and internal standard, guarantees specificity for the analysis.
In conclusion: the method presented here for analysis for tocainide offers the advantages of rapid sample preparation without the use of large volumes of volatile and (or) toxic extraction solvents; very good sensitivity, even with small serum volumes; good reproducibility; use of underivatized samples; and the specificity of mass spectrometry. 505-507(1986) The Veterans Administration provided resources; Dr. Al Smith (Chief, Clinical Pathology, Veterans Administration Medical Center, Bay Pines, FL) critically evaluated the manuscript.
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